Eli Lilly says Verve's gene editor lowers cholesterol levels in early study

Treatment was center of $1 billion buyout

Eli Lilly announced on Monday that a high dosage of its gene-editing therapy significantly decreased cholesterol levels by 62% among participants in a clinical trial. This development serves as a promising initial assessment of the potential for a one-time treatment aimed at aiding individuals in reducing their LDL cholesterol, commonly referred to as "bad" cholesterol.

Lilly obtained the therapy, VERV-102, through its $1 billion acquisition of Verve Therapeutics last year. Company executives regard it as a possible solution for the widespread prevention of heart disease, which remains the leading cause of death globally. This is particularly relevant as numerous patients find it challenging to adhere to existing traditional medications aimed at lowering cholesterol levels.

Importantly, the Phase 1 study reported no treatment-related serious adverse events, a significant outcome considering that Verve's initial candidate had to be withdrawn due to safety issues.